The phosphorylation status of CRKL has been used as a marker to predict the efficacy of tyrosine kinase inhibitors (TKI; e.g. imatinib and nilotinib) in the treatment of CML patients [6, 7]. This evidence concerns the gene CRKL and chronic myelogenous leukemia, BCR-ABL1 positive.